ProFactor Pharma LTD
  • Home
  • About Us
  • Haemophilia
  • Technology
  • Team
  • Contact
  • News
Select Page

ProFactor Pharma (PFP) realise further capital injection – August 2022

by Richard Cruse | Sep 20, 2022 | Uncategorized

ProFactor Pharma is pleased to announce completion of a further investment round. The investment will enable PFP to progress the company’s clinical stage Recombinant Human Factor VIII to market and to engage with commercial licensing opportunities. The funding...

Articles

  • ProFactor Pharma (PFP) realise further capital injection – August 2022 September 20, 2022
  • Health Tech World – Interview – Ending the Haemophilia Drug Shortage (23 November 2021) November 24, 2021
  • Profactor Pharma Announces Issuance of Indian and Eurasian Patent Covering a high yielding cell line for treatment of Haemophilia A March 31, 2021
  • Profactor Pharma completes optimisation of process for manufacture of lowest cost recombinant FVIII January 31, 2021
  • World-wide inequalities in Haemophilia care. Things are getting better? January 19, 2021
  • Outstanding technical progress July 15, 2020
  • Too many Haemophilia A patients still receiving inadequate or no treatment January 26, 2020
  • Paul Gerskowitch Joins PFP Board November 15, 2019
  • PFP secures new investment of £2m to achieve pre-clinical trials October 30, 2019
  • Press Release March 2015 – Penrose enquiry December 16, 2015
  • Home
  • About Us
  • Haemophilia
  • Technology
  • Team
  • Contact
  • News